U.K. To Decide On Lipitor Patent Wednesday

Law360, New York (October 10, 2005, 12:00 AM EDT) -- In a case that foreshadows one of the most closely watched patent lawsuits in the U.S., a U.K. judge will rule Wednesday on Ranbaxy’s patent challenge to the world’s most widely prescribed drug, Pfizer’s cholesterol fighter Lipitor.

If Pfizer’s patent assertion is denied and Ranbaxy is permitted to produce a generic version, Pfizer stands to lose billions of dollars. The U.K. represents about 7% of the global market for Lipitor.

Globally, Lipitor had sales of $10.3 billion last year, by far overshadowing sales of runner-up Zocor,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.